Novo Nordisk A/S, a leading global healthcare company, has announced the initiation of a share repurchase program on August 7, 2024, as part of a larger 12-month buyback plan set to conclude on February 6, 2025. The current program, which follows the Safe Harbour Rules, involves the repurchase of B shares amounting to DKK 2.4 billion and will run until November 4, 2024. Since the start of the program, Novo Nordisk has bought back 130,250 B shares for a total of DKK 112,401,277. These transactions are separate from the company's incentive programs, which have seen a net transfer of 23,030 B shares. As a result, Novo Nordisk now holds 12,540,136 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's stock is traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.

Novo Nordisk A/S, a leading global healthcare company, has announced the initiation of a share repurchase program on August 7, 2024, as part of a larger 12-month buyback plan set to conclude on February 6, 2025. The current program, which follows the Safe Harbour Rules, involves the repurchase of B shares amounting to DKK 2.4 billion and will run until November 4, 2024. Since the start of the program, Novo Nordisk has bought back 130,250 B shares for a total of DKK 112,401,277. These transactions are separate from the company's incentive programs, which have seen a net transfer of 23,030 B shares. As a result, Novo Nordisk now holds 12,540,136 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's stock is traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.